Toxicogenomics profiling of bone marrow from rats treated with topotecan in combination with oxaliplatin: a mechanistic strategy to inform combination toxicity by Myrtle Davis et al.
ORIGINAL RESEARCH ARTICLE
published: 12 February 2015
doi: 10.3389/fgene.2015.00014
Toxicogenomics profiling of bone marrow from rats treated
with topotecan in combination with oxaliplatin: a
mechanistic strategy to inform combination toxicity
Myrtle Davis1*, Jianying Li2,3, Elaine Knight1, Sandy R. Eldridge1, Kellye K. Daniels4 and
Pierre R. Bushel3,5*
1 Toxicology and Pharmacology Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA
2 Kelly Government Solutions, Research Triangle Park, NC, USA
3 Microarray and Genome Informatics Group, National Institute of Environmental Health Sciences, Research Triangle Park, NC, USA
4 Toxicology and Pathology Services, Southern Research Institute, Birmingham, AL, USA
5 Biostatistics Branch, Division of Intramural Research, National Institute of Environmental Health Sciences, Research Triangle Park, NC, USA
Edited by:
Richard Nass, Indiana University
School of Medicine, USA
Reviewed by:
Garry Wong, University of Eastern
Finland, Finland
Douglas Mark Ruden, Wayne State
University, USA
*Correspondence:
Myrtle Davis, Toxicology and
Toxicogenomics, 9609 Medical
Center Drive, Bethesda, MD 20892,
USA
e-mail: myrtledavis@mail.nih.gov;
Pierre R. Bushel, Bioinformatics and
Toxicogenomics, 111 T. W. Alexander
Drive, PO Box 12233, Research
Triangle Park, NC 27709, USA
e-mail: bushel@niehs.nih.gov
Combinations of anticancer agents may have synergistic anti-tumor effects, but enhanced
hematological toxicity often limit their clinical use. We examined whether “microarray
profiles” could be used to compare early molecular responses following a single dose of
agents administered individually with that of the agents administered in a combination. We
compared the mRNA responses within bone marrow of Sprague-Dawley rats after a single
30min treatment with topotecan at 4.7mg/kg or oxaliplatin at 15mg/kg alone to that of
sequentially administered combination therapy or vehicle control for 1, 6, and 24 h. We also
examined the histopathology of the bone marrow following all treatments. Drug-related
histopathological lesions were limited to bone marrow hypocellularity for animals dosed
with either agent alone or in combination. Lesions had an earlier onset and higher
incidence for animals given topotecan alone or in combination with oxaliplatin. Severity
increased from mild to moderate when topotecan was administered prior to oxaliplatin
compared with administering oxaliplatin first. Notably, six patterns of co-expressed genes
were detected at the 1 h time point that indicate regulatory expression of genes that
are dependent on the order of the administration. These results suggest alterations in
histone biology, chromatin remodeling, DNA repair, bone regeneration, and respiratory
and oxidative phosphorylation are among the prominent pathways modulated in bone
marrow from animals treated with an oxaliplatin/topotecan combination. These data also
demonstrate the potential for early mRNA patterns derived from target organs of toxicity
to inform toxicological risk and molecular mechanisms for agents given in combination.
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INTRODUCTION
Effective anticancer treatments generally require the use of a com-
bination of drugs. A challenge for combination treatment is a shift
in the extent and severity of adverse effects for the combination
compared with either of the agents when given alone. Most Phase
I trials for targeted agent combinations have been designed to
escalate the drug doses to the maximally tolerated dose (MTD).
Data that are now available suggest that combinations of molec-
ularly targeted agents (MTAs) can lead to more severe toxicities
and that dose reduction is often required for regimens to be tol-
erable (Kummar et al., 2010). Although empirical approaches
are currently being used, a preclinical assessment that can pro-
vide a mechanistic basis for adverse effects of drug combinations
is desirable. Systems-based computational approaches that inte-
grate, transcriptomics, proteomics, or other profiling data may
be useful to discover network-level alterations in normal cell
signaling in normal tissues after in vivo administration.
Toxicogenomics, the application of transcription profiling to
toxicology (Nuwaysir et al., 1999), has been widely used for
elucidating the molecular and cellular actions of drugs and
chemicals on biological systems, flagging potential for toxic-
ity (before functional damages occur), and providing classi-
fication of known or new toxicants based on signatures of
gene expression (Guerreiro et al., 2003; Ruepp et al., 2005;
Bushel et al., 2007; Chengalvala et al., 2007; Ganter et al.,
2008; Ryan et al., 2008). In the current study, we examined the
benefit of applying transcriptomics to assess risk of enhanced
tar-get organ toxicity when two drugs are used in combina-
tion. We hypothesized that an additive toxicity pattern can be
inferred from comparative analysis of early mRNA responses
of tissues obtained following a single dose of two agents given
individually with the agents given in combination. We also
anticipate that biological pathways revealed by gene response
patterns will provide a more comprehensive understanding
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of toxicity and provide a mechanistic basis for experimental
investigation.
For this initial proof of concept, we used the chemotherapeu-
tic agents topotecan and oxaliplatin, which have been explored
for use in combination for treating various cancers (Alexandre
et al., 2002; Tortora et al., 2002; Elkas et al., 2007). Topotecan
is a topoisomerase I (Topo I) inhibitor that forms a complex on
DNA leading to double-stranded DNA breaks and ultimately cell
death. Oxaliplatin is a diaminocyclohexane platinum compound
that acts as a DNA alkylating agent. Pre-exposure to oxaliplatin
transiently increased Topo I-mediated single-strand breaks, sug-
gesting that DNA platination might stimulate Topo I DNA cleav-
age activity providing a rationale for the use of platinum-based
compounds with topoisomerase inhibitors (Goldwasser et al.,
1999). Combinations of topo I inhibitors and platinum deriva-
tives, in general, have synergistic anti-tumoral effects, but their
clinical use is limited by hematological toxicity, which is some-
what dependent on the sequence of drug administration. We
also wanted to examine the possibility that the acute response
of a target organ to a single dose of treatment and obtain-
ing an associated molecular footprint, can aid in investigation
about mechanisms of target-mediated toxicity. In our study, a
single dose of topotecan was given to Sprague Dawley rats either
before or after administration of oxaliplatin to determine whether
combination administration or the order of administration influ-
enced bone marrow toxicity and the microarray signature profile
obtained following combined administration of the drugs. We
found that a single dose intravenous infusion of topotecan or
oxaliplatin, given alone or in combination, to male rats resulted
in the formation of histopathological lesions in bone marrow
(hypocellularity) observed after only1 h of topotecan adminis-
tration or 6 h after oxaliplatin administration. The severity of
bone marrow lesions increased when topotecan was given prior
to oxaliplatin compared with oxaliplatin given prior to topote-
can indicating that severity of toxicity was affected by sequence of
administration.
We also characterized the molecular and pathway signatures
in bone marrow for a topotecan/oxaliplatin combination based
on global gene expression analyses and comprehensive bioinfor-
matics profiling. Based on our results, we propose that single
dose rodent studies and microarray analysis of mRNA patterns
derived from bone marrow represents a mechanistic approach to
evaluate the potential risk of enhanced toxicity for combination
agents.
MATERIALS AND METHODS
TEST ARTICLES
Oxaliplatin (1.2 g; NSC 266046) and topotecan (310mg; NSC
609699) were supplied by the National Cancer Institute (NCI)
and received at Southern Research Institute on October
19, 2010. The test articles were received on dry ice and
then refrigerated. The following reagents were received from
the NCI chemical repository and stored at room temper-
ature and used in the preparation of dose formulations:
5% dextrose injection, USP (PSS World Medical; Kennesaw,
GA); Saline Solution 0.9% (saline; Nova Tech Inc.; Grand
Island, NE).
DOSE FORMULATION PREPARATION
Dose formulations of topotecan were prepared in saline to con-
tain a nominal concentration of topotecan hydrochloride of
1.2mg/mL. For preparation, the appropriate amount of saline
was added to the required amount of topotecan hydrochloride
and the formulation was stirred until a solution was obtained.
Dose formulations of oxaliplatin were prepared in 5% dextrose
in water (D5W) to contain a nominal concentration of oxali-
platin of 3.75mg/mL. For preparation, the appropriate amount
of D5W was added to the required amount of oxaliplatin and the
formulation was stirred until a solution was obtained.
ANIMALS AND TREATMENTS
The 96 Sprague-Dawleymale rats used in this study were obtained
from Charles River Laboratories, Inc. (Raleigh, NC). Each rat was
procured with an indwelling femoral vein cannula. Animals were
given a unique identification number by ear punch. Prior to dos-
ing on day 1, the catheter of each rat was checked for patency. Rats
with patent catheters were randomly assigned to one of 8 treat-
ment groups. On day 1, the rats were approximately 8 weeks of age
and weighed between 271.2 and 342.2 g. Teklad Certified Rodent
Diet 2016C (Harlan; Madison, WI) and tap water (Birmingham
public water supply) were provided ad libitum to the rats prior to
and throughout the study. The animals were individually housed
in solid-bottom polycarbonate cages on stainless steel racks in
a room maintained at a temperature of 70–79◦F and a relative
humidity of 44–66%. Room lights were controlled by an auto-
matic timer set to provide a 12/12 light:dark cycle. Heat-treated
hardwood chip bedding (P. J. Murphy Forest Products, Corp.;
Montville, NJ) was used as bedding material. No known contam-
inants were present in the food, water, or bedding that would be
expected to interfere with or affect the outcome of the study. Cage
size and animal care conformed to the guidelines of the Guide
for the Care and Use of Laboratory Animals (National Research
Council, 2011) and the U.S. Department of Agriculture through
the Animal Welfare Act (Public Law 99-198).
The study design (with doses administered) is provided in
Table 1. A dose slightly below theMTDwas chosen for these stud-
ies. Since the goal of our study was to investigate gene responses
induced by a single dose that could potentially be premonitory
for toxicity, we administered a dose that would not be con-
founded by marked pathological changes in the tissue. The MTD
for oxaliplatin in rats was referenced in the Center for Drug
Evaluation and Research pharmacology review of NDA # 21-
492 (FDA, 2002) and is close to the human clinical dose of 85
mg/m2. The dose selected for topotecan was derived from the
time course of the hematological effects of topotecan after two
consecutive daily administrations to tumor-bearing rats that was
described using a semiphysiological model to predict the hemato-
toxic effects of topotecan (Friberg et al., 2002; Segura et al., 2004).
Each rat was administered a single intravenous (IV) infusion
dose, given over a 30min interval, of topotecan (of 4.7mg/kg),
oxaliplatin (15mg/kg), or respective vehicle control formulation
(see Table 1). Thirty minutes after the end of the first infusion,
topotecan, oxaliplatin, or a respective vehicle control formulation
was administered by IV infusion, given over a 30min interval.
For example, animals given topotecan (or corresponding vehicle)
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Table 1 | Study design.
Group Treatment Dose of topotecan Dose of oxaliplatin No. animals No. animals per
(mg/kg) (mg/kg) per group necropsy time point (Hours)
1 6 24
1 0.9% NaCl(30min infusion) followed by D5W
(30min infusion)
0 0 12 4 4 4
2 D5W(30min infusion) followed by 0.9%
NaCl(30min infusion)
0 0 12 4 4 4
3 Topotecan (30min infusion) followed by D5W
(30min infusion)
4.7 (first infusion) 0 12 4 4 4
4 Oxaliplatin (30min infusion) followed by 0.9%
NaCl (30min infusion)
0 15 (first infusion) 12 4 4 4
5 Topotecan (30min infusion) followed by
Oxaliplatin (30min infusion)
4.7 (first infusion) 15 (second infusion) 12 4 4 4
6 Oxaliplatin (30min infusion) followed by
Topotecan (30min infusion)
4.7 (second infusion) 15 (first infusion) 12 4 4 4
7 0.9% NaCl(30min infusion) followed by
Oxaliplatin (30min infusion)
0 15 (second infusion) 12 4 4 4
8 D5W(30min infusion) followed by Topotecan
(30min infusion)
4.7 (second infusion) 0 12 4 4 4
during the first infusion were given oxaliplatin (or correspond-
ing vehicle) during the second infusion. All doses were delivered
at a flow rate of approximately 4mL/kg/30min. Infusion vol-
umes were based on the mean body weight of animals on the
day prior to dosing. Rats were observed twice daily during the
pre-study and study periods for signs of mortality and morbidity.
Detailed clinical examinations of each rat were collected prior to
euthanasia. Each animal was weighed on the day of dosing prior
to dose administration (for the calculation of infusion rate; data
not reported).
HISTOPATHOLOGY
Samples of femur bone marrow were collected for histopathology
and fixed in 10% neutral buffered formalin. All slides were exam-
ined by a veterinary pathologist. Each lesion was listed and coded
by the most specific topographic and morphologic diagnoses,
severity, and distribution using Toxicology Data Management
System (TDMS) nomenclature. A four-step grading system was
used to rank the severity of microscopic lesions for comparison
among groups.
TISSUE COLLECTION AND RNA ISOLATION
At 1, 6, or 24 h after the completion of dosing, 4 rats per
group were euthanized by CO2 asphyxiation. Immediately after
euthanasia, bone marrow from left femurs was collected for RNA
isolation. Bone marrow was flushed from bone using RNAlater®
and refrigerated (approximately 2–8◦C) for at least 24 h and then
stored at or below −20◦C.
RNA isolation from individual tissues was accomplished using
an RNeasy microarray kit (QIAGEN Inc., Valencia, CA). After
extraction, the RNA concentration of each sample was deter-
mined using a RiboGreen assay. The RNA Integrity Number
(RIN) of each sample was determined using an Agilent 2100
Bioanalyzer with 2100 Expert Software (Version B.02.06.S1418;
Agilent, Santa Clara, CA). Only samples with a RIN of 7.5 or
higher were deemed acceptable for gene expression analysis. Two
samples, one from group 3 and a group 2 did not meet the
RIN for further processing. Each of the remaining RNA sam-
ples were diluted to the required concentration (250 ng/μL) and
then stored at or below −70◦C prior to shipment to Expression
Analysis (Durham, NC) for microarray hybridization.
MICROARRAY HYBRIDIZATION
Microarray data was generated by Expression Analysis (Durham,
NC). RNA samples were converted into labeled target anti-
sense RNA (cRNA) using the Single-Round RNA Amplification
and Biotin Labeling System (Enzo Life Sciences, Farmingdale,
NY). Briefly, 2.5μg of total RNA was converted into double
stranded cDNA via reverse transcription using an oligo-d(T)
primer-adaptor. This cDNA was purified and used as a tem-
plate for in vitro transcription using T7 RNA polymerase and
biotinylated ribonucleotides. The resulting cRNA was purified
using magnetic beads and quantitated using spectrophotometry.
Next, 11μg of purified cRNA was fragmented using a 5X frag-
mentation buffer (200mM Tris-Acetate, pH 8.1, 500mM KOAc,
150mM MgOA), then a hybridization cocktail was prepared and
added to the fragmentation product using the Hybridization,
Wash and Stain kit (Affymetrix, Santa Clara, CA), applied to
Affymetrix GeneChip Rat Genome 230 2.0 Arrays, and incubated
at 45◦C for 16 h. Following hybridization, arrays were washed and
stained using standard Affymetrix procedures before scanning on
the Affymetrix GeneChip Scanner 3000 using factory PMT set-
tings. Data extraction was completed with Expression Console
software using a target scaling of 500. The data are available
in the Chemical Effects in Biological Systems (CEBS) reposi-
tory (Waters et al., 2008) under investigation accession number:
007-00005-0000-000-2 and study accession number: 007-00005-
0001-000-3 as well as in the Gene Expression Omnibus (GEO)
www.frontiersin.org February 2015 | Volume 6 | Article 14 | 3
Davis et al. Toxicogenomics profiling of bone marrow
(Edgar et al., 2002; Barrett et al., 2013) under accession number
GSE63902.
DETECTION OF DIFFERENTIALLY EXPRESSED GENES (DEGs)
Data analysis was performed using the Bioconductor R package
(Gentleman, 2005). We used the package “affyQCReport,” com-
bined with principal component analysis (PCA), for array quality
control (i.e., outliers detection). After the one outlier sample was
excluded (sample 1344-05H, 6 h oxaliplatin followed by vehicle),
the remaining Affymetrix raw CEL files were preprocessed using
the robust multichip average (RMA) algorithm (Irizarry et al.,
2003a,b); which includes background correction, quantile nor-
malization, and summarization by the median polish approach.
Next, we performed PCA-based gene filtering on the log base 2
scale data from RMA using the package “pvac,” where the filtering
is based on a score measuring consistency among probes within a
probe set (Lu et al., 2011). Finally, the statistical significance of
DEGs was accessed by comparison of treated samples to time-
matched controls using the empirical Bayes based method known
as a limma t-test, which is available in the bioconductor package
limma (Smyth, 2005). Analyses were carried out in two batches,
where the first batch includes samples from groups 1, 3, 5, and 7,
and the second batch contains samples from groups 2, 4, 6, and 8,
(see study design Table 1).
DETECTION OF PATTERNS OF CO-EXPRESSED GENES
log base 2 scaled data of the probes remaining after the PCA-
based filtering were analyzed for expression patterns across the
samples using methodology known as extracting gene expression
patterns and identifying co-expressed genes (EPIG) (Chou et al.,
2007). For each treatment group, the pixel intensity data for each
probe was converted to a ratio value by dividing the average probe
pixel intensity by the 1 h control samples from that group and
then taking the log base 2. EPIG uses correlations (r) across all
the sample groups, signal to noise ratio (s/n) within groups of
samples, and magnitude of fold change (FC) for a probe within
a group to first detect all potential patterns in the data, and then
categorize each probe to the pattern that is most statistically sig-
nificant in terms of the correlation between the probe profile and
the pattern. The parameter settings for the EPIG analysis were the
defaults: r = 0.8, s/n = 2.5, and FC = 0.5. We used a minimum
pattern cluster size of 6 for finding all potential patterns.
ENRICHMENT OF BIOLOGICAL PROCESSES BASED ON DEGs
For each DEGs list derived at p < 0.01 and absolute fold change
>2, the Affymetrix GeneChip Rat Genome 230 2.0 Array probe
sets were mapped to the Gene Ontology (GO) biological pro-
cesses (BPs) of the genes they represent using version 2.10.1 of
the GO database and the rat2302 database. The 2.14.0 version of
the “topGO” Bioconductor package in R was used to perform
enrichment of GO BP terms. The classic algorithm (where the
significance of a node is considered independent of the signifi-
cance of the neighboring nodes) and the Kolmogorov-Smirnov
test statistic were used for enrichment with node size of at least 5
DEGs. Significance of enrichment was set to p < 0.05. The union
of the enriched GO BPs terms from all of the DEGs lists yielded
641 terms. BP terms which were not significant had missing p-
values and were imputed with 1.0. The 641 GO BPs terms were
clustered based on the −log base 10 p-values and using Pearson
correlation (r) as the dissimilarity metric with average linkage
grouping. Clusters (those with a 1- r ≥ 0.9) of GO BP terms
(n ≥ 30) were labeled according to the node having themaximum
number of paths to it within the GO BP subtree directed acyclic
graph derived from the terms in the cluster.
PATHWAY ANALYSIS OF GENES WITHIN PATTERNS EXTRACTED BY
EPIG
Clusters of genes identified by EPIG were analyzed using Pathway
Studio 9® (Ariadne Genomics, Rockville, MD), to find enriched
pathways. Enrichment analysis in Pathway Studio 9® was per-
formed by Gene Set Enrichment Analysis (GSEA) and Sub-
Network Enrichment Analysis (SNEA) algorithms. Functional
enrichment was performed using Fisher’s exact test. SNEA enrich-
ment in Pathway Studio was calculated using the Mann-Whitney
test, a non-parametric method for comparing the medians of
two distributions. Significant enrichment was set at p < 0.05.
For GSEA, pathways with fewer than 3 entities represented were
filtered from the data sets.
VISUALIZATION OF GENE EXPRESSION ON PATHWAYS
To visualize the changes of gene expression within a particu-
lar pathway, Pathvisio version 3.1.3 (Van Iersel et al., 2008) was
used to overlay the average of the log base 2 ratio values from
the replicate samples onto biological pathways obtained from
Wikipathways (Kelder et al., 2012). The cluster IDs fromUniGene
(according to the rat Rn4 July 12, 2012 release of refSeq version
54) was used to map the probe sets on the microarray to the genes
on the Wikipathways.
GENE REGULATORY NETWORK RECONSTRUCTION
The Gene Regulatory Network Inference (GRNInfer) software
(Wang et al., 2006) with default parameter settings (λ = 0.0 and
threshold = 1 × 10−6 controlling the sparseness and the com-
plexity of the network respectively) was used to reconstruct the
interactions of the 19 genes in the p53 signaling Wikipathway
that had gene expression data mapped. The gene expression data
from microarray probes mapping to the same UniGene cluster
were averaged and then biological replicates at each time point
were averaged. GRNInfer uses linear programming and singular
value decomposition of the time point gene expression data to
derive of the interactions of the genes within the network given
the above thresholds. For topotecan followed by oxaliplatin and
oxaliplatin followed by topotecan, the averaged gene expression
measures at each time point were used to reconstruct the gene
regulatory network depending of the order of administration of
the two drugs.
RESULTS
CLINICAL OBSERVATIONS
No mortality occurred during the study and no drug- or
treatment-related adverse clinical signs were observed for any ani-
mal during the study. The mean body weight of animals in the
individual dose groups ranged from 300 to 310 g on the day of
dosing.
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HISTOPATHOLOGY
Bone marrow hypocellularity was observed in the bone marrow
of animals dosed with topotecan, oxaliplatin, or a combina-
tion of these two drugs (Figure 1 and Table 2). Minimal bone
marrow hypocellularity consisted of an approximately 10–20%
decrease in the normal population of cells which reside in the
bonemarrow in comparison with control animals. The remaining
cell population consisted primarily of band and mature granu-
locytes (neutrophils and eosinophils), mature erythrocytes, and
megakaryocytes. Occasionally apoptotic cells were observed in
the bone marrow of some animals. These lesions were observed
as early as 1 h after the end of topotecan administration and
6 h after the end of oxaliplatin administration. Bone marrow
hypocellularity was observed at a higher and earlier onset of
incidence in animals that received topotecan alone or topote-
can in combination with oxaliplatin than in dose groups that
received only oxaliplatin. One-hour post-treatment, bone mar-
row hypocellularity was observed for animals in all of the dose
groups administered topotecan alone or topotecan in combi-
nation with oxaliplatin, but not in the dose groups given only
oxaliplatin. There also appeared to be an increase in sever-
ity of bone marrow suppression from mild to moderate when
topotecan was given prior to oxaliplatin than when oxaliplatin
was given prior to topotecan. These data support a sequence
dependency for the severity of bone marrow toxicity for this
combination.
RNA ISOLATION
The integrity of each isolated RNA sample was equal to or greater
than the protocol-specified minimum RIN (7.5), with the excep-
tion of two samples. Acceptance criteria could not be obtained
for bone marrow collected from one of the animals from group
3 (topotecan/D5W treated group) and one animal in group 2
(D5W/saline vehicle control group). These samples were not
submitted for gene expression analysis.
PATTERNS OF CO-EXPRESSED GENES
We focused our analysis on uncovering groups of genes display-
ing similarity in their expression patterns and comparing the gene
responses between treatment groups. The EPIG approach uti-
lizes the underlying structure of gene expression data to extract
patterns and identify co-expressed genes that are responsive to
experimental conditions (Chou et al., 2007). The response pat-
terns of genes were used to select gene sets that represent potential
signatures for effects of the combination treatments that dif-
fered from that of the single agents. As shown in Figures 2A–C,
several patterns of gene expression are induced or repressed rel-
ative to time-matched controls at the 1-, 6-, or 24 h time points
FIGURE 1 | Representative images of bone marrow hypocellularity in
femur from male rats 24h after a single 30min IV infusion dose of
oxaliplatin, topotecan or combination of oxaliplatin followed by
topotecan. Hematoxylin and eosin stained tissue sections; 10X objective;
bars = 100μm. (A) Male rat exposed to vehicle control. (B) Minimal
hypocellularity in male rat exposed to oxaliplatin. (C) Mild hypocellularity in
male rat exposed to topotecan. (D) Moderate hypocellularity in male rat
exposed to oxaliplatin followed by topotecan. Bone marrow hypocellularity
was graded based on the estimated percentage of cell loss with minimal
hypocellularity = 10–20% cell loss, mild hypocellularity = 30–40% cell loss,
moderate hypocellularity = 50–60% cell loss, and marked hypocellularity =
greater than 60% cell loss.
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Table 2 | Histopathology of the bone marrow.
1h POST-DOSE: SEVERITY OF TEST ARTICLE-RELATED MICROSCOPIC LESIONS
Tissue, microscopic
lesion
0.9%saline
D5W
D5W
0.9% saline
Topotecan/
D5W
Oxaliplatin
0.9% saline
Topotecan
Oxaliplatin
Oxaliplatin
Topotecan
0.9% saline
oxaliplatin
D5W/
Topotecan
Bone marrow,
hypocellularity
NA NA Minimal to
mild
NA Minimal Minimal to
mild
NA Minimal
6h POST-DOSE: SEVERITY OF TEST ARTICLE-RELATED MICROSCOPIC LESIONS
Tissue, microscopic
lesion
0.9%saline
D5W
D5W
0.9% saline
Topotecan
D5W
Oxaliplatin
0.9% saline
Topotecan
Oxaliplatin
Oxaliplatin
Topotecan
0.9% saline
oxaliplatin
D5W
Topotecan
Bone marrow,
hypocellularity
NA NA Minimal to
mild
Minimal to mild Minimal
to mild
Mild Minimal to
mild
Minimal
to mild
24h POST-DOSE: SEVERITY OF TEST ARTICLE-RELATED MICROSCOPIC LESIONS
Tissue, microscopic
lesion
0.9%saline
D5W
D5W
0.9% saline
Topotecan
D5W
Oxaliplatin
0.9% saline
Topotecan
Oxaliplatin
Oxaliplatin
Topotecan
0.9% saline
oxaliplatin
D5W
Topotecan
Bone marrow,
hypocellularity
NA NA Mild Minimal to mild Mild to
moderate
Mild to
moderate
Minimal to
mild
Mild to
moderate
respectively. Patterns that identified differences between individ-
ual treatment and combination treatment groups are marked
with an asterisk in Supplementary Figures 1–3. The Venn dia-
grams in Supplementary Figure 4 reveal that there is little overlap
of co-expressed genes changes (of 4-fold or more) between oxali-
platin and topotecan except for at the 24 h time point where 73
genes overlap.
The heat map in Figure 3A shows gene expression patterns
across all treatment groups and time points. There is a clear time
response in the patterns of gene expression from the treatments
where by the 24 h time point, the patterns of expression are either
maximally induced or maximally repressed. A list of represen-
tative pattern-specific genes showing at least 4-fold differences
from their respective controls at the 24 h bone marrow collec-
tion time point is provided in Table 3 (up-regulated) and Table 4
(down-regulated). Notably, several genes related to chondrogen-
esis, bone repair, and differentiation were profoundly increased
in response to combination treatment when compared to indi-
vidual treatments. As show in the visualization of just the 1 h
time points (Figure 3B), the co-expressed genes in patterns 8, 9
and pattern 11 vary depending on whether topotecan was given
before or after the vehicle or oxaliplatin. On other hand, the co-
expressed genes in patterns 14–16, vary depending on whether
oxaliplatin was given before or after the vehicle. The 244 probes in
patterns 8, 9, and 11, representing 59 co-expressed genes, enrich
for pathways related to mRNA splicing, splicesomes, metabolism,
cell cycle and DNA replication. The 188 probes in patterns 14–16,
representing 45 co-expressed genes, enrich for pathways related
to chromosome organization, chromatin packaging and remodel-
ing. Full lists of genes derived from each pattern with absolute fold
change of 4 or greater from their respective controls and p < 0.05,
are provided in Supplementary Table 1.
PATHWAY ANALYSIS OF GENES WITHIN PATTERNS EXTRACTED BY
EPIG
Gene lists within patterns revealing clear differences between con-
trol and treatment groups for each time-point were used to obtain
pathway enrichment profiles by gene set enrichment analysis
(Subramanian et al., 2005). Supplementary Tables 2–4 are lists
(1 h, 6 h and 24 h respectively) of pathways from gene set enrich-
ment analyses carried out against reference pathways, provided
by Ariadne, within the designated patterns. Pathways common
to multiple patterns were also identified and shown in Figure 4.
The pathways commonly enriched in all patterns evaluated at
all treatment times were those pathways related to chromatin
remodeling and cell cycle regulation. Pathways derived from the
lists of genes obtained from bone marrow samples 1 and 6 h
after dosing were particularly enriched with pathways related to
DNA repair, histone biology, cell cycle regulation, hypoxia, glu-
tathione metabolism, and respiratory and oxidative phosphoryla-
tion. These regulatory events provide evidence of target-mediated
biology for the drug treatments that can be potentially used as a
basis for additional toxicodynamic modeling as early as 1 h after
administration of a single dose.
DIFFERENTIALLY EXPRESSED GENES
Using statistical comparisons of treatments to time-matched con-
trols (absolute fold change>2 and FDR< 0.01), 3304 gene probes
in total were detected as differentially expressed (Supplementary
Table 5). Principal component (PC) analysis of the gene expres-
sion data from the differentially expressed gene probes projected
the samples in 3-dimensional space (Supplementary Figure 5)
and revealed that PC #1 separates the samples by time and the top
3 PCs grouped the biological replicates by treatment very well.
ENRICHMENT OF BIOLOGICAL PROCESSES
Genes detected as differentially expressed at each time point
(Supplementary Table 5) were used to enrich Gene Ontology
(GO) biological processes (BPs). There were 641 GO BPs
(Supplementary Table 6) significant (p < 0.05) from the union of
all the lists (Supplementary Tables 7–12) [each one matching the
order represented by the treatments in Figure 5]. Figure 5 shows
the clustering of the 641 GO BPs terms based on the –log base
10 p-values. Clusters (those with a correlation value ≥ 0.9) of
GO BP terms (n ≥ 30) were labeled according to the node having
the maximum number of paths to it within the GO BP subtree
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FIGURE 2 | EPIG patterns across treatments groups 1, 6, and 24h
post-treatment. The average of the log base 2 ratio (treated sample to
the average of the time-matched control) from the top 6 expression
profiles with the highest degree of correlation are plotted and displayed
on the y-axis. The x-axis contains the treatments and the order of
exposure. Oxali = oxaliplatin (15mg/kg) and Topo = topotecan
(4.7mg/kg). (A) Patterns extracted by EPIG of mRNA from bone marrow
samples that were collected 1 h post-treatment administration. The row
labeled 1st denotes which agent was administered first. (B) Same as A
except analysis of mRNA from bone marrow samples that were
collected 6 h post-treatment. (C) Same as A except analysis of mRNA
from bone marrow samples collected 24 h post-treatment.
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FIGURE 3 | Heatmap of gene expression data analyzed by EPIG. (A)
The 1393 gene probes categorized to the 16 EPIG patterns (y-axis color
column) across the 1, 6, and 24 h time points are in rows and the
samples are in columns. (B) Patterns 8, 9, 11, 14–16 from the samples
at just the 1 h time point. The labeling of samples is according to the
time and order in which the agent was given (either 1st or second).
Oxali is oxaliplatin (15mg/kg) and Topo = topotecan (4.7mg/kg). Veh1 is
the vehicle used for Oxali, and Veh2 is the vehicle used for Topo. The
data is the log base 2 ratio (treated sample to the average of the
time-matched control) and the scale on the bottom displays the color
range for the log base 2 ratio values. Red denotes upregulation, blue
downregulation, and gray relatively no change.
directed acyclic graph derived from the terms in the cluster. DNA
damage-signal transduction by p53 was highly enriched by the
oxaliplatin exposure at the 6 h time point when it was given first
but not second. Oxaliplatin given second elicited an ATP catabolic
process at 6 h and positive regulation of epithelial tomesenchymal
transition at 24 h. Topotecan when given second at 6 h impacted
Ras GTPase activity in a positive regulation manner. The GTP
catabolic process was enriched at the 6 h time point regardless
of the order of administration of topotecan or oxaliplatin. Very
few BPs were enriched at the 1 h time points. However, the bio-
logical processes highly connected to ventricular cardiac muscle
cell development were enriched in a time-dependent manner,
maximizing at the 24 h time point.
REGULATION OF p53 SIGNALING, APOPTOSIS AND CELL CYCLE
RELATED GENES
Pathways related to DNA damage and p53-mediated cell cycle
arrest were identified as highly connected and were uniquely
Frontiers in Genetics | Toxicogenomics February 2015 | Volume 6 | Article 14 | 8
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enriched in some samples. We then visualized the changes in
gene expression within the rat p53 signaling Wikipathway at the
24 h time point in the study (Figure 6). As indicated by the rel-
ative expression to time-matched controls, MDM2, GADD45,
SCOTIN, CASP8, and IGFB3 were up-regulated whereas the
cyclins, p53, SIAH, GTSE1, and PARP1 were down-regulated.
Regulation of several genes that also play roles in the apoptosis
pathways (Figure 4) and cell cycle regulation (Figure 4) was also
observed at the 24 h time point.
p53 SIGNALING PATHWAY GENE REGULATORY NETWORK
RECONSTRUCTION
The enrichment of GO biological processes from the samples
where oxaliplatin is given first followed by vehicle for topotecan
revealed DNA damage, regulation of p53 signaling transduction
(Figure 5). In addition, the overlay of gene expression data on
the p53 signaling pathway revealed regulation of key compo-
nents of the cascade at 24 h (Figure 6). We therefore sort out to
reconstruct the gene regulatory network based on the 19 genes
mapped to the rat p53 signaling Wikipathway. This would allow
us to compare the gene interactions from the time point data in
the samples where topotecan is given first followed by oxaliplatin
vs. when oxaliplatin is given first followed by topotecan. Using the
Gene Regulatory Network Inference (GRNInfer) software with
the default setting to control the sparseness and the complexity of
the network reconstruction, gene networks based on the average
of the four replicate time point studies for each order of admin-
istration were revealed (Figure 7). When topotecan is given first
followed by oxaliplatin, MDM2 proto-oncogene, E3 ubiquitin
protein ligase (MDM2) and GADD45g are central hubs interact-
ing with p53, cyclin-dependent kinases, several cysteine-aspartic
acid proteases (CASPs), BID, two CASPs (CASP8 and CASP3) and
other components (Figure 7A). On the other hand, when oxali-
platin is given first followed by topotecan, CASP8 and the G-2 and
S-phase expressed 1 gene (GTSE1) are the central hubs of the net-
work interacting with p53, the cyclin-dependent kinases, CASP9,
Kras, FAS, BID and other components (Figure 7B). Essentially
the activation and inactivation shown for components in the net-
works are caused by different central regulators depending on the
order of administration.
DISCUSSION
This study was conducted to determine whether a single dose
rodent study and toxicogenomics profiling informs the potential
risk for enhanced bone marrow toxicity for the combined admin-
istration of clinically effective chemotherapeutic agents. Genomic
profiling is a mature technology that has been strategically and
efficiently used in preclinical drug safety assessment to predict
safety issues that may be revealed in more lengthy, longer-term
studies (Ryan et al., 2008; Huang et al., 2010). In addition, global
gene expression data have shown promise in generating hypothe-
ses about early onset “toxicity triggers” (Hamadeh et al., 2010).
Topotecan is a particularly difficult drug to use in combination
because of the need for dose attenuation when given in com-
bination regimens. Having a method to identify the potential
for enhanced bone marrow toxicity when topotecan is given in
combination with a second agent would be particularly useful.
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FIGURE 4 | Scatter plots of pathways enriched in patterns derived
from bone marrow collected post-treatment with topotecan,
oxaliplatin, or a combination. Clusters of genes identified by EPIG were
then analyzed using Gene Set Enrichment Analysis (GSEA) and
Sub-Network Enrichment Analysis (SNEA) algorithms to find enriched
pathways. (A) One hour post-treatment. (B) Six hours post-treatment.
(C) Twenty-four hours post-treatment. The numbers on the x-axis denote
the EPIG pattern which contained the genes that enriched the pathways
labeled on the y-axis. A square represents a pathway that was enriched by
the genes in the given EPIG pattern.
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FIGURE 5 | Clustering of the Enrichment of GO BPs. Clustering and
heatmap based on the −log base 10 (p-values) of the 641 Gene
Ontology (GO) biological processes (BPs) for each treatment and time
point. The GO BPs are on the y-axis, the samples are on the x-axis. The
enriched GO BPs were obtained from limma analysis DEGs (absolute
fold change >2 and FDR < 0.01). Significance of enrichment was set to
p < 0.05. Missing values were imputed as 0 (−log base 10(1), i.e.,
p = 1), Clustering of the pathways were performed using Pearson
correlation dissimilarity (r ) and average linkage grouping. Clusters (those
with a 1- r ≥ 0.9) of GO BP terms (n ≥ 30) were labeled according to
the node having the maximum number of paths to it within the GO BP
subtree directed acyclic graph derived from the terms in the cluster. The
color in the legend denotes the significance of enrichment. The more
red the heat map color, the more significant the enrichment.
During the study, no drug-related adverse clinical signs were
observed for any animals treated with topotecan or oxaliplatin
alone or in combination. Histopathological evaluation of bone
marrow established the presence of drug-related lesions in bone
marrow (hypocellularity) in animals administered topotecan or
oxaliplatin. Although our preclinical results highlight the need to
consider the sequence of administration in a clinical protocol, our
histopathological findings were not consistent with the sequence
dependency of the severity of bone marrow toxicity that was
reported in clinical studies of cisplatin and topotecan (De Jonge
et al., 2000). In clinical trials, both neutropenia and thrombocy-
topenia were more severe when cisplatin was administered prior
to topotecan and there were significantly lower absolute neu-
trophil count nadirs and percentage decrements in neutrophil
and platelet counts with this sequence. Our results are consistent
with the observation that oxaliplatin exhibits a favorable toxi-
city profile with a substantially lower incidence and severity of
nephrotoxicity, ototoxicity, and myelosuppression.
Topotecan and other anticancer agents may cause DNA dam-
age via mechanisms other than direct binding to DNA replication
machinery. For example, camptothecin and analogs have been
reported to induce apoptosis through a mechanism involving
reactive oxygen species and oxidative stress pathways (Li et al.,
2009). Similarly, pretreatment of mice with the anti-oxidant
quercetin was reported to reduce topotecan-induced genotox-
icity and cytotoxicity (Bakheet, 2011). Quercetin also reduced
oxidative stress markers in topotecan treated bone marrow cells
(Bakheet, 2011). Thus, it is feasible that the early effects of topote-
can we observed in bone marrow are related to oxidative stress.
Although it is clear that most of the in vivo biology for topotecan
would be expected to be mediated by TOP1, the observed enrich-
ment of genes related to ROS neutrophil-mediated cell damage
and hypoxia-induced mitochondrial damage pathways, support
additional mechanistic possibilities.
Traditional gene expression analysis has used two samples sta-
tistical tests for each comparison of interest or analysis of variance
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FIGURE 6 | Overlay of gene expression on the p53 signaling pathway.
The rat p53 signaling pathway is overlaid with the average of the log base 2
ratio values from the replicate samples. Red denotes induction, green
repression and yellow no change. Gray indicates that the gene was not
mapped. The legend illustrates the segmentation of the genes according to
the data from a given treatment.
(ANOVA) model when the data are from studies with a factorial
design. Upon selecting differentially expressed genes (DEGs), the
next step is usually pooling the lists of DEGs to cluster analyze
the data for visualization of patterns of gene expression across the
samples. A limitation to this strategy is that the process of select-
ing the genes before detecting the patterns can omit genes that
have salient expression profiles correlated across the samples. This
caveat is of major concern when analyzing expression data com-
prised of genes whose expression are altered at low drug exposures
or perturbed only for a short duration. The EPIG approach (Chou
et al., 2007) was developed specifically for toxicogenomics and
other series type studies where the algorithm uses an ANOVA-
like statistical evaluation of the patterns of gene expression but
also takes into account correlation of genes within an expression
pattern. In the EPIG two-step approach, all significant patterns
in the data are extracted first, followed by categorization of gene
expression profiles.
Application of the EPIG method to our microarray data
and subsequent pathway and gene regulatory network analyses
allowed identification of genes, pathways and regulatory inter-
actions that appear to represent promising biomarker signa-
tures for bonemarrow toxicity. Pathways related to p53 signal-
ing, DNA repair, histone biology, cell cycle regulation, hypoxia,
glutathione metabolism, and respiratory and oxidative phospho-
rylation reflect the biological effects of either treatment on the
bone marrow. The considerable enrichment of pathways involved
with DNA repair and chromatin remodeling is remarkably well-
aligned with the biological mechanisms and downstream effects
of topotecan. The interplay between chromatin remodeling and
DNA repair factors is infrequently discussed in relation to DNA
damage response mechanisms of the bone marrow. Our analysis
highlights a meaningful relationship between chromatin remod-
eling complexes and mechanisms of bone marrow toxicity and
repair that warrants further investigation.
An interesting biological response pathway of genes related
to tissue injury was derived from our analysis of co-expressed
genes (Supplementary Table 1). Regulation of chondrogenesis,
bone repair, and differentiation was identified for some of the
genes that were profoundly increased in response to combination
treatment when compared to individual treatments. These genes
were matrix metallopeptidase 12 (MMP12); transgelin (TAGLN,
SM22α); cyclin D1 (CCND1); serpin peptidase inhibitor, clade H
(heat shock protein 47), member 1 (collagen binding protein1)
(SERPINH1); tenascin C (TNC); ADAM metallopeptidase with
thrombospondin type 1 motif, 9 (ADAMTS9); and bone mor-
phogenetic protein 2 (BMP2). TNC is an extracellular matrix
glycoprotein that is specifically and transiently expressed upon
tissue injury. SERPINH1 functions as a molecular chaperone dur-
ing collagen synthesis and maturation (Nagata, 1998; Lamande
and Bateman, 1999; Razzaque and Taguchi, 1999; Hendershot
and Bulleid, 2000). Upon tissue damage, TNC regulates a wide
variety of pathways that mediate both inflammatory and fibrotic
processes, enabling effective tissue repair (Truong et al., 1996;
Chiquet-Ehrismann and Chiquet, 2003; Midwood and Orend,
2009). TAGLN is a shape change sensitive 22 kDa actin-binding
protein of the calponin family that may regulate conversion of
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FIGURE 7 | Reconstruction of the p53 signaling gene regulatory
network. The 19 genes mapped in the rat p53 signaling Wikipathway
is used to reconstruct the network based interactions derived from
the gene expression data. For (A) topotecan followed by oxaliplatin
and (B) oxaliplatin followed by topotecan, the average of the biological
replicates’ gene expression data at each time point were used to
reconstruct the gene regulatory network depending of the order of
administration of the two drugs. A red arrow indicates activation, a
blue arrow indicates inactivation. The labeling of the nodes is based
on the UniGene symbol.
adult bone marrow-derived mesenchymal stem cells into smooth
muscle cells (SMCs) and is an early marker of smooth muscle dif-
ferentiation (Lawson et al., 1997). Expression of ADAMTS9 was
shown to be up-regulated during chondrogenic differentiation of
human mesenchymal stem cells (Boeuf et al., 2012).
Gene profiling of bone marrow environment cells revealed
distinct expression profiles for genes encoding for ADAMs and
their inhibitors (Bret et al., 2011). In the current study, all cells
expressed ADAMTSs genes at a low level, with the exception of
bone marrow stromal cells. BMP2 plays an essential role in chon-
drocyte proliferation and maturation during endochondral bone
development (Shu et al., 2011). Similarly, MMPs are required
for both endochondral and intramembranous ossification during
bone repair and it is likely that this gene response is a sensitive
indicator of initial degradation of extracellular matrix. These gene
responses are similar to microarray studies that identified gene
responses during stages of bone marrow-ablation-induced bone
regeneration (Wise et al., 2010). Taken together, the observed
gene responses may represent a unique biomarker panel for bone
marrow that will flag early tissue damage onset followed by chon-
drogenesis and intramembranous regeneration processes. The
11- and 7-fold increases in MMP12 and TAGLN observed 24 h
post-treatment with topotecan compared with a 54- and 17-fold
increase when topotecan treatment is given with oxaliplatinmight
represent an additive response for the combination. The effect of
treatment combinations on these responses likely reflects a change
in the extent of damage and response of the bone marrow to
injury.
Among the genes showing the most profound decreases in
response to all treatments are several genes for proteins regulating
shape and hemolysis of erythrocytes. We noted a 26-fold decrease
in spectrin, alpha, erythrocytic 1 (elliptocytosis 2) (SPTA1).
Mutations in spectrin genes that render red cells deficient in
spectrin are associated with abnormal cytoskeletal architecture
making erythrocytes susceptible to hemolysis (Kakhniashvili,
2001; Broderick and Winder, 2005). A similar contribution to
actin dynamics in platelets has been elucidated for pleckstrin-2
(PLEK2) (Lian et al., 2009), and we report a 14-fold decrease in
PLEK2 mRNA in response to topotecan alone. In addition, a 9-
fold decrease was noted in Ankyrin 1 (ANK 1), an erythrocyte
membrane protein that is defective in many patients with heredi-
tary spherocytosis, a common hemolytic anemia. Taken together
our results demonstrate a clear connectivity between the most
profoundly affected genes and the clinical adverse effect profile
for topotecan. For example, a recent clinical study designed to
determine the dose of weekly oral topotecan allowing safe admin-
istration in patients with recurrent gynecologic malignancies, 13
(11.1%) doses of drug were held because of anemia in 8 patients,
neutropenia in 7, or thrombocytopenia in 2 (VonGruenigen et al.,
2012).
This study reports gene response data in bone marrow post-
treatment with topotecan or oxaliplatin alone and in combination
following a single administration. There are no comparable gene
expression studies on the effect of the combination of the two
agents used here, but one study, based on 8mg/kg oxaliplatin in
rat bone marrow at 24 h, was found in a public data source. That
public (yet unpublished) study is deposited in the Drug Matrix
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8.0 database (Ganter et al., 2005) hosted by the NIEHS/NTP
at https://ntp.niehs.nih.gov/drugmatrix/index.html. One pub-
lished study compares the effect of oxaliplatin in ovarian cancer
spheroids (L’Esperance et al., 2008). This underscores the unique-
ness and novel aspect of our combination study. Supplementary
Figures 6, 7 show the paucity of overlap of the oxaliplatin DEGs
from our current study and those from the aforementioned public
studies (Drug Matrix bone marrow and ovarian cancer spheroids
respectively). Caution is needed in interpreting these compar-
isons due to the differences in the doses administered, the target
cell type/tissue, the array platforms, significance test and the
annotations based on gene symbol to compare results. We pro-
vide a comprehensive list of genes from ourmicroarray analysis of
bone marrow taken at various time points after treatment of rats
to enable additional analysis and hypothesis generation (http://
tools.niehs.nih.gov/cebs3/ui/). Although we will continue to ana-
lyze these data for biological response pathways and mechanistic
pathways for toxicity, we publish these data to encourage other
investigators to employ alternative analysis methods and propose
additional relationships relevant to the observed bone marrow
responses and treatments.
The use of a single dose study using genomic endpoints as a
measure of enhanced bone marrow toxicity is exciting for several
reasons. This approach could be incorporated into a mechanism-
based risk evaluation and a single dose administration can be
readily incorporated as an in vivo or in vitro screening paradigm.
For example, attempts to validate in vitro bone marrow systems
could use these data to explore and identify molecular anchors
that translate from in vitro to in vivo. Second, this proof of concept
revealed that the molecular responses in bone marrow toxicity is
much earlier than previously documented preclinical histopatho-
logical observations of topotecan toxicity. Examining the acute
response of a target organ to chemotherapy and obtaining a
molecular footprint associated with this response in combina-
tion with a targeted agent can guide us along new avenues of
investigation about mechanisms of target-mediated toxicity. At
this point, these data represent qualitative information that is
relevant to understandingmechanisms of toxicity. The initial phe-
notypic anchoring of these data with additional endpoints may
ultimately provide a more comprehensive understanding of path-
ways underlying bone marrow toxicities. Indeed, other reports
have highlighted the potential use of toxicogenomics data to
enable integrative risk assessment and biomarker identification
(Ellinger-Ziegelbauer et al., 2011; Matheis et al., 2011). We plan
to apply this approach to other target organs and additional anti-
cancer drug combinations to examine the broader implications of
this strategy.
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